Shenzhen - Delayed Quote CNY

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)

16.52
+1.74
+(11.77%)
At close: May 23 at 3:04:19 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
NameTitlePayExercisedYear Born
Mr. Wang Chao General Manager -- -- 1982
Mr. Shicheng Li CPA Head of Accounting & Financial Director -- -- 1982
Mr. Maorong Yu Secretary of the Board & Deputy GM -- -- 1981

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

No. 36, Jingha 2nd Road
Beijing Economic and Technological Development Zone
Beijing, 100176
China
86 10 6751 9888 https://www.staidson.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
492

Description

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release tablets, Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

Corporate Governance

Staidson (Beijing) BioPharmaceuticals Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

May 17, 2019 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

688336.SS Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
54.67
-3.56%
 
301301.SZ Yili Chuanning Biotechnology Co.,Ltd.
13.12
+2.02%
 
IFRX InflaRx N.V.
1.8500
+1.65%
 
KRON Kronos Bio, Inc.
0.6887
+0.10%
 
1530.HK 3SBIO
20.050
+0.35%
 
HOPHF Hemogenyx Pharmaceuticals Plc
1.2400
0.00%
 
TRSBF 3SBio Inc.
3.0000
0.00%
 
2269.HK WuXi Biologics (Cayman) Inc.
23.850
-0.83%
 
CLDX Celldex Therapeutics, Inc.
20.35
-0.10%
 
MDGL Madrigal Pharmaceuticals, Inc.
267.56
-2.12%